Bicky

TargetCancer has a dedicatedNational Molecular Tumor Board for rare cancers. Experts from Harvard, MD Anderson, MCW, City of Hope, John Hopkins, Foundation Medicine, TargetCancer Foundation. And more gather weekly to help patients either be rare cancers 🎯🎯💡💡🔥

@MarcMachaalani @DrChoueiri @YaleIMed @BraunMDPhD @VincentWenxinXu @Clara__Steiner @eddy_saad @yekeduz_emre @ReneeSaliby @AminNassarMD @thenasheffect @TalalZarif1 Congratulations Marc!

Thrilled to have matched at @YaleIMed! Beyond grateful to my amazing mentors, friends, and family for supporting me every step of the way! #Match2026

A great team changing the way we treat and think about urology cancer.

Part of the @DanaFarber_GU team during #GU26 @DanaFarber @OncoAlert

Breaking news from @ASCO #GU26 👉Adding belzutifan to adjuvant pembrolizumab significantly improves disease free survival (HR: 0.72)👉Congrats @drchoueiri & team for changing SOC again in pts with #kidneycancer @kidneycan @OncoAlert @urotoday

Data from the ph3 LITESPARK-011 are finally out and brilliantly presented by Dr.@motzermd. Belzutifan + lenvatinib vs. cabozantinib in ICI-pretreated advanced RCC : - Significantly improved PFS (HR 0.70, p=.00007; median 14.8 mo vs 10.7 mo, IA2) - Achieved higher ORR (52.6% vs 39.6%, IA1) - DOR: median 23.0 mo vs 12.3 mo - OS: more follow-up ongoing. A major advance introducing a new treatment option in post-ICI RCC. #GU26 #RCC @OncLive @OncoAlert

A little history recap: 2021: KN564 is positive 2024: KN564 shows the first OS improvement in adjuvant therapy in ANY type of cancer 2026: let's do better than KN564, pembro/bel > pembro @DrChoueiri

Now enrolling through @ALLIANCE_org - STRIKE! (A032201) exploring the role of Tivozanib with pembrolizumab following resection of ccRCC - check out our TIP at #GU26 @ASCO @DanaFarber_GU clinicaltrials.gov/study/NCT06661…

#GU26 KEYNOTE-905/EV-303 surpasses platinum for neoadjuvant Urothelial cancer @ASCO @OncoAlert

So proud of our Gelb Center for Translational Research manager Jasmine Lee for her poster summarizing our experience with on-treatment PSMA PET/CT in patients receiving ADT+ARPI for mHSPC, with a majority eventually being able to take a treatment break. @DanaFarber_GU

Our very own @VanAllenLab Keynote Speaker at #GU26 How AI will change our oncology research and patient future ➡️ Ask Why, For Whom, and How? @ASCO @DanaFarber_GU @DrChoueiri

Reimagining cancer research and care in the age of AI. Mind-blowing talk by our @DanaFarber_GU colleague Eli Van Allen on how AI is reshaping precision oncology, from molecular insight to real-time clinical decision-making. #GU26 @VanAllenLab @harvardmed @OncoAlert

Congrats Team KYN-905 and Christof Vulsteke @crighent 🇧🇪 ! @merck @NEJM

Congratulations to our Lank Center Medical Oncolgists who made the 2026 Boston Magazine Top Doctors list! @mishabeltran @DrChoueiri @BradMcG04 & Mary-Ellen Taplin

Outstanding inaugural meeting of the international @WIN_Consortium Rare Cancers Committee chaired by @Dr_R_Kurzrock with a distinguished group of experts and global leaders @SewantiLimaye @JTrentMDPhD @GSholler @targetcancer @RueterJens @LiaTsimberidou @DrTonyLetai @bickythapa02 @AllenChankowsky There are great opportunities for innovative progress with global impact using the latest AI predictive algorithms, technology platforms including tissue and blood-based nucleic acid and other biomarker assays, novel omics, digital pathology, functional precision medicine, consensus guidelines among others. There is much existing data that is low hanging fruit and opportunities for learning from every patient as we try to help every patient. Rare cancers and how they are managed is foundational and eventually will extend to N-of-1 for many other cancers currently thought of as less rare. With the new WIN Consortium Precision Oncology Fellowship, WIN Consortium Disease Committees, discussions with genomics, other omics, AI, patient advocacy groups and pharma companies we are optimistic about progress in the coming years.

Dr. @felixfengmd was a devoted mentor in the field of prostate ca. Today would have been his 50th birthday 💔 Join us in supporting a @ConquerCancerFD Career Development Award honoring his legacy @MaryFengMD @DrChoueiri support.conquer.org/p2p/site/nGSMo…

9/VHL-independent YAP1 dependency in #ccRCC: @gu_xiangming et al. (@oncogenejournal) show hyperactivated YAP1 sustains tumor progression across oxygen states. In normoxia YAP1 = FGF boosts tumor + endothelial proliferation, In hypoxia YAP1 = VEGF promotes angiogenesis. Verteporfin “completely blocked” xenograft growth. @MGHMedicine nature.com/articles/s4138…

On to the 2025 GU TRANSLATIONAL/LAB Papers: 1/Major advance in #mCRPC with @li_haolong et al. (@NatureGenet). This study engineered a fluorescent AR reporter and ran genome-scale CRISPR screens to discover PTGES3 directly regulates androgen receptor stability in prostate cancer. High PTGES3 predicts therapy resistance and poor survival @FredHutch nature.com/articles/s4158…

3/ POTOMAC (Phase III): adding 1 year of durvalumab to BCG induction + maintenance In BCG-naive high-risk NMIBC significantly improved DFS vs BCG alone. 32% risk reduction for recurrence or death (HR 0.68) at ~5-yr f/u. Manageable safety profile. Supports IO + BCG as a potential new standard in high-risk NMIBC. @tompowles1 @TheLancet @nealshore @mdesantis234 @AstraZeneca thelancet.com/journals/lance…

10/ Final OS analysis of the EMBARK trial (#ESMO2025): in high-risk biochemical recurrent prostate cancer, enzalutamide+leuprolide significantly improves OS vs leuprolide alone. 8-yr OS 78.9% vs 69.5% (HR 0.60). Enzalutamide monotherapy did not improve OS vs leuprolide. Supports combined AR blockade + ADT in high-risk biochemical recurrent prostate cancer. @NEJM nejm.org/doi/full/10.10…